NCT05403723 2026-02-19
Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLC
University of Maryland, Baltimore
Phase 1 Suspended
University of Maryland, Baltimore
M.D. Anderson Cancer Center
Stanford University
Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal
GlaxoSmithKline